Reply to Letter by Cyrta et al, entitled “Additional considerations on aberrant BRG1 (SMARCA4) expression in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)”-Reference-Cited by-同舟云学术

Reply to Letter by Cyrta et al, entitled “Additional considerations on aberrant BRG1 (SMARCA4) expression in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)”

Published:2024-08-21 Issue: Volume: Page:
ISSN:0147-5185
Container-title:American Journal of Surgical Pathology
language:en
Short-container-title:

Author:

Mazibrada Jasenka¹,Croce Sabrina²,Foulkes William D.³⁴,McCluggage W. Glenn⁵

Affiliation:

1. Department of Pathology, Norfolk and Norwich University Hospital, UK

2. Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center Bordeaux, France

3. Cancer Research Program and the SCCOHT/SMARCA4 Registry and Biobank, Research Institute, McGill University Health Centre, Montreal, QC Canada

4. Departments of Human Genetics, Medicine and Oncology, McGill University, Montréal, Québec, Canada

5. Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference5 articles.

1. Unusual aspects of small cell carcinoma of the ovary of hypercalcaemic type: retained smarca4 immunohistochemical staining and positive staining with TLE1;Mazibrada;Am J Surg Pathol,2023

2. SMARCA4-mutated atypical teratoid/rhabdoid tumor with retained brg1 expression;Masliah-Planchon;Pediatr Blood Cancer,2016

3. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis;Hasselblatt;Acta Neuropathol,2014

4. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma;Köbel;J Pathol Clin Res,2016

5. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility;Köbel;Int J Gynecol Pathol,2019